Intuitive Surgicalのda Vinciロボット手術プラットフォームは、高齢化する人口が回復期間の短い低侵襲手術への需要を高める中、ますます不可欠な存在となっています。
Intuitive Surgicalは医療技術とイノベーションの交差点に位置するヘルスケア株であり、そのda Vinciロボット手術システムは世界中の病院に導入されて年間数百万件の低侵襲手術を実施し、システムが増設されるごとに成長する器具・アクセサリー・サービス契約からの高マージンの繰り返し収益を生み出しています。
Intuitive Surgicalはロボット支援外科手術の標準を定めたda Vinciシステムを持ち、外科自動化分野で支配的なロボット株です。膨大な導入ベース、消耗品からの繰り返し収益、および新たな術式への展開が、医療分野における最高の純粋プレイロボット投資としての地位を確立しています。
Data updated Feb 15 · Source: Twelve Data
Intuitive Surgical is the undisputed leader in robotic-assisted surgery, with its da Vinci surgical systems installed in thousands of hospitals worldwide. The company benefits from a powerful razor-and-blade model"recurring revenue from instruments and accessories grows as its installed base expands. With an EPS of $6.80 and strong procedure volume growth, fundamentals remain solid.
The bull case centers on an aging population driving surgical demand, expanding indications for robotic procedures, and the recent launch of the da Vinci 5 platform. Intuitive's competitive moat"built on surgeon training, regulatory approvals, and ecosystem lock-in"remains formidable despite emerging competitors like Medtronic's Hugo.
The bear case is valuation. At a P/E of 71.45, the stock prices in years of flawless execution. The recent 17.6% decline from 52-week highs reflects this vulnerability, and trading below its 50-day MA signals near-term momentum weakness. Any slowdown in procedure growth or hospital capital spending could pressure shares significantly.
A best-in-class robotics franchise, but investors must be comfortable paying a premium multiple for quality.
Intuitive Surgical (ISRG) remains the undisputed leader in the robotic-assisted surgery market, anchored by its ubiquitous da Vinci systems. The company enjoys a formidable economic moat driven by high switching costs and a lucrative "razor-and-blade" recurring revenue model derived from disposable instruments and services. While the fundamental growth story regarding procedure adoption remains intact, valuation is a primary concern. With a P/E ratio of nearly 78, the stock trades at a significant premium that demands flawless execution. Currently trading below its 50-day moving average of $547.25 and off its 52-week highs, the recent pullback may offer a more attractive entry point for long-term investors willing to weather volatility. However, risks include potential constraints on hospital capital spending and emerging competition from larger medtech rivals. ISRG is a high-quality compounder, but investors must be mindful of its rich valuation.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
すべてのトレーダーは頭の中で良さそうに見える戦略を持っています。バックテストは、それが実際に機能するかどうかを調べる方法です。ここは戦略を適切にテストする方法、どのメトリクスが重要か、そしてほとんどのバックテスト結果が本当とは思えないほど良い理由です。
Powered by Rexiew